

Markers of haemolysis and renal tubular injury after catheter ablation for atrial fibrillation using pulsed field and radiofrequency energy

Marek Hozman, MD, PhD¹, Barbora Bacova, MD, PhD², Dalibor Herman, MD, PhD¹, Ivana Fiserova, MSc, PhD³, Sabri Hassouna, MD¹, Vaclav Melenovsky, MD¹, Jakub Karch, MSc¹, Jana Vesela, MSc, PhD¹, Pavel Osmancik, MD, PhD¹




1: Dept. of Cardiology, University Hospital Kralovske Vinohrady, Charles University, Prague, Czech Republic

Dept. of Laboratory Hematology, Central Laboratories, University Hospital Kralovske Vinohrady, Prague, Czech Republic

3: Dept. of Molecular Biology, Charles University, Prague, Czech Republic









Introduction





Introduction

However, rare cases of ***acute renal failure secondary to tubular injury caused by intravascular haemolysis*** have been described after PFA procedures with a very high number (> 100) of PF pulses




Genier et al., Europace, 2023
Qian et al., Am J Kidney Dis. 2010


Introduction



Introduction




Introduction

Current AKI nomenclature	Description	Interpretation
Subclinical AKI	Tubular damage biomarker indicates damage, yet SCr is not elevated	<ul style="list-style-type: none"> • SCr is an insensitive marker of tubular damage • Elevation of SCr requires damage to >50% of nephron mass. Damage to a portion of the kidney is not detected
Transient versus sustained AKI	 <ul style="list-style-type: none"> • SCr elevation <3 days versus SCr elevation >3 days¹ • SCr return to <10% of baseline versus >72 h of azotaemia • RIFLE-AKI resolved by 72 h versus RIFLE-AKI persisting ≥72 h 	A single measurement of SCr at the time of patient encounter does not provide prospective information on the kinetics of SCr; transient AKI includes volume expansion (dilutional azotaemia), whereas sustained AKI is not
Severe AKI	<p>Alpha Glutathione S-Transferase, Kidney Injury Molecule 1, Clusterin, Cystatin C, Neutrophil Gelatinase-Associated Lipocalin, Osteopontin, (Micro)albumin</p> <p>Rasi G Letter of support for drug-induced renal tubular injury biomarker(s). European Medicines Agency https://www.ema.europa.eu/en/documents/other/letter-support-drug-induced-renal-tubular-injury-biomarkers_en.pdf (2016).</p>	Quantitative tool only in steady state; clinical studies have demonstrated that AKI can be associated with biomarkers of tubular injury
Subacute AKI		Muscle, accumulates slowly in serum; patients cannot be diagnosed at the time of patient encounter using SCr criteria
Late onset AKI	<ul style="list-style-type: none"> • AKI occurring >7 days after birth • AKI occurring ≥5 days from admission • AKI occurring 48 h after admission 	Optimal use of SCr requires correlating its values with clinical course

Introduction

	Description	Serum levels elevated after injury
L	Expressed in renal tubular epithelial cells and released in case of cell damage.	After 2 hours
I	Not detectable in normal kidney tissue but expressed at high levels in proximal tubule epithelial cells after injury.	Within 12 hours



Aims of the study

To investigate the impact of ablation energy (**PFA vs. radiofrequency ablation (RFA)**) on the plasma concentration of:

(1) cell-free haemoglobin (CFH)

(2) and markers of renal tubular injury: neutrophil gelatinase associated lipocalin and kidney injury molecule 1 (NGAL and KIM-1).



Methods

A prospective nonrandomized study that included a consecutive cohort of patients who underwent AF ablation (PFA or RFA) in one centre.

PFA procedures:

Deep sedation / GA (LMA): propofol + sufentanil / remimazolam + ketamine

A pentaspline Farawave catheter (Boston Scientific)

Paroxysmal AF = PVI

Non-paroxysmal AF = PVI + PW + Mi



RFA procedures:

CARTO 3 mapping system (JaJ Medtech)

Ablation catheter SMARTTOUCH / QDOT (JaJ Medtech)

Ablation index 400 – 450 on the anterior wall, 300 – 350 on the posterior wall; high-power short-duration applications were avoided

Paroxysmal AF = PVI

Non-paroxysmal AF = additive lesions at the discretion of the operator



Methods


Blood samples:

T1: CFH, NGAL, and KIM-1

T2: CFH

T3: CFH, NGAL, and KIM-1

The concentrations of CFH, NGAL and KIM-1 were determined using the ELISA technique.



Results: Baseline characteristics

Characteristics	RFA group (N = 23)	PFA group (N = 47)	P - value
Paroxysmal AF, N (%)	14 (60.9)	27 (57.4)	0.99
Female gender, N (%)	9 (39.1)	19 (40.4)	1.00
Age, mean (SD), years	67.4 (10.2)	62.9 (9.70)	0.08
BMI, mean (SD), kg/m ²	28.4 (4.0)	29.9 (5.1)	0.19
LA (PLAX), mean (SD), mm	43.3 (4.9)	41.8 (5.9)	0.30
LVEF, mean (SD), %	56.2 (12.1)	58.1 (6.0)	0.54
Hypertension, N (%)	13 (56.5)	35 (74.4)	0.21
Diabetes mellitus, N (%)	1 (4.3)	10 (21.3)	0.09
Coronary artery disease, N (%)	1 (4.3)	4 (8.5)	1.00
Baseline creatinine, mean (SD), μ mol/L	91.7 (22.1)	88.8 (22.1)	0.44


Calculated glomerular filtration rate:

PFA group: 5 (10.6%) stage 2 and 2 (4.3%) stage 3 (chronic kidney disease (CKD))

RFA group: 1 (4.3%) stage 2 and 2 (8.7%) stage 3 (CKD)

Results


23 subjects underwent RFA and 47 PFA (*mean number of PF impulses 52.85 ± 18.37 , range 32-100*).



Results: CFH


Cell-free haemoglobin in time, RFA group

Friedman test, $\chi^2(2) = 3.37, p = 0.19, n = 20$



Cell-free haemoglobin in time, PFA group



Friedman test, $\chi^2(2) = 39.99, p = <0.0001, n = 47$



In the PFA cohort, a significant increase in CFH concentration was observed immediately after ablation with CFH declining to baseline values one day after the procedure ($93.4 \pm 65.1 \mu\text{g/mL}$ vs. $2394.9 \pm 1966.1 \mu\text{g/mL}$ vs. $93.4 \pm 65.1 \mu\text{g/mL}$ $P < 0.001$). A significant periprocedural increase in CFH concentrations was observed in the RFA cohort.



Results: NGAL

Biomarker	RFA group (N = 21)		P - value	PFA group (N = 47)		P - value
	T1	T3		T1	T3	
NGAL, mean (SD), ng/mL	108.3 ± 33.8	116.3 ± 32.2	0.49	98.6 ± 31.7	98.5 ± 38.1	0.78



Results: KIM-1

Biomarker	RFA group (N = 21)		P - value	PFA group (N = 47)		P - value
	T1	T3		T1	T3	
NGAL, mean (SD), ng/mL	108.3 ± 33.8	116.3 ± 32.2	0.49	98.6 ± 31.7	98.5 ± 38.1	0.78
KIM-1, mean (SD), pg/mL	29.2 ± 31.7	23.0 ± 24.4	0.09	38.4 ± 56.8	42.6 ± 76.4	0.50



Compared to baseline, **neither the PFA nor the RFA group showed a significant increase in NGAL or KIM-1 concentrations postoperatively.**

Study limitations

limitations:

1. Serum concentration of biomarkers analysed
Urine analysis more sensitive
2. Nonrandomised study
3. Lower mean number of PF applications
More than 70 applications seem to have better sensitivity and specificity to predict haemolysis
4. Long-term follow-up data missing

Conclusions

Compared to RFA, PFA leads to significant periprocedural haemolysis.

However, no increase in markers of renal tubular injury was observed in the cohort in which the total number of PF applications was less than 100.